Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles

Cancer Cell

Volumn 12, Issue 6, 2007, Pages 501-513

  Fröhling, Stefan ^a   Scholl, Claudia ^a   Levine, Ross L ^a   Loriaux, Marc ^g   Boggon, Titus J ^b   Bernard, Olivier A ^c   Berger, Roland ^c   Döhner, Hartmut ^d   Döhner, Konstanze ^d   Ebert, Benjamin L ^a,e   Teckie, Sewit ^e   Golub, Todd R ^a,e   Jiang, Jingrui ^a   Schittenhelm, Marcus M ^f   Lee, Benjamin H ^a   Griffin, James D ^a   Stone, Richard M ^a   Heinrich, Michael C ^h,i   Deininger, Michael W ^h   Druker, Brian J ^a,h   Gilliland, D Gary ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

CELLCYCLE

Indexed keywords

DNA; FLT3 LIGAND; PHOSPHOTRANSFERASE;

ALLELE; ANIMAL CELL; ARTICLE; CARCINOGENESIS; CATALYSIS; DNA SEQUENCE; ENZYME ACTIVATION; FUNCTIONAL ASSESSMENT; GENE IDENTIFICATION; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 36649000489     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2007.11.005     Document Type: Article

References (56)

1. Bagrintseva K., Schwab R., Kohl T.M., Schnittger S., Eichenlaub S., Ellwart J.W., Hiddemann W., and Spiekermann K. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood 103 (2004) 2266-2275
2. Bell D.W., Gore I., Okimoto R.A., Godin-Heymann N., Sordella R., Mulloy R., Sharma S.V., Brannigan B.W., Mohapatra G., Settleman J., and Haber D.A. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat. Genet. 37 (2005) 1315-1316
3. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., and Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann. Intern. Med. 103 (1985) 620-625
4. Choudhary C., Schwable J., Brandts C., Tickenbrock L., Sargin B., Kindler T., Fischer T., Berdel W.E., Muller-Tidow C., and Serve H. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 106 (2005) 265-273
5. Clark J.J., Cools J., Curley D.P., Yu J.C., Lokker N.A., Giese N.A., and Gilliland D.G. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood 104 (2004) 2867-2872
6. DeAngelo D.J., Stone R.M., Heaney M.L., Nimer S.D., Paquette R.L., Klisovic R.B., Caligiuri M.A., Cooper M.R., Lecerf J.M., Karol M.D., et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics. Blood 108 (2006) 3674-3681
7. Fiedler W., Serve H., Dohner H., Schwittay M., Ottmann O.G., O'Farrell A.M., Bello C.L., Allred R., Manning W.C., Cherrington J.M., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
8. Forrest W.F., and Cavet G. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science 317 (2007) 1500
9. Frohling S., Scholl C., Gilliland D.G., and Levine R.L. Genetics of myeloid malignancies: Pathogenetic and clinical implications. J. Clin. Oncol. 23 (2005) 6285-6295
10. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., Rahman N., and Stratton M.R. A census of human cancer genes. Nat. Rev. Cancer 4 (2004) 177-183
11. Gari M., Goodeve A., Wilson G., Winship P., Langabeer S., Linch D., Vandenberghe E., Peake I., and Reilly J. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br. J. Haematol. 105 (1999) 894-900
12. Getz G., Hofling H., Mesirov J.P., Golub T.R., Meyerson M., Tibshirani R., and Lander E.S. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science 317 (2007) 1500
13. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., et al. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007) 153-158
14. Griffith J., Black J., Faerman C., Swenson L., Wynn M., Lu F., Lippke J., and Saxena K. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol. Cell 13 (2004) 169-178
15. Grundler R., Miething C., Thiede C., Peschel C., and Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 105 (2005) 4792-4799
16. Grundler R., Thiede C., Miething C., Steudel C., Peschel C., and Duyster J. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood 102 (2003) 646-651
17. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., Lister T.A., and Bloomfield C.D. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J. Clin. Oncol. 17 (1999) 3835-3849
18. Jeffers M., Schmidt L., Nakaigawa N., Webb C.P., Weirich G., Kishida T., Zbar B., and Vande Woude G.F. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA 94 (1997) 11445-11450
19. Jiang J., Greulich H., Janne P.A., Sellers W.R., Meyerson M., and Griffin J.D. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 65 (2005) 8968-8974
20. Jones T.A., Zou J.Y., Cowan S.W., and Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47 (1991) 110-119
21. Karlsson R., Zheng J., Xuong N., Taylor S.S., and Sowadski J.M. Structure of the mammalian catalytic subunit of cAMP-dependent protein kinase and an inhibitor peptide displays an open conformation. Acta Crystallogr. D Biol. Crystallogr. 49 (1993) 381-388
22. Kelly L.M., Liu Q., Kutok J.L., Williams I.R., Boulton C.L., and Gilliland D.G. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99 (2002) 310-318
23. Knapper S. FLT3 inhibition in acute myeloid leukaemia. Br. J. Haematol. 138 (2007) 687-699
24. Knapper S., Mills K.I., Gilkes A.F., Austin S.J., Walsh V., and Burnett A.K. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: The induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 108 (2006) 3494-3503
25. Lee B.H., Williams I.R., Anastasiadou E., Boulton C.L., Joseph S.W., Amaral S.M., Curley D.P., Duclos N., Huntly B.J., Fabbro D., et al. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene 24 (2005) 7882-7892
26. Lee J.C., Vivanco I., Beroukhim R., Huang J.H., Feng W.L., Debiasi R.M., Yoshimoto K., King J.C., Nghiemphu P., Yuza Y., et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 3 (2006) e485
27. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
28. Levinson N.M., Kuchment O., Shen K., Young M.A., Koldobskiy M., Karplus M., Cole P.A., and Kuriyan J. A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol. 4 (2006) e144
29. Ley T.J., Minx P.J., Walter M.J., Ries R.E., Sun H., McLellan M., DiPersio J.F., Link D.C., Tomasson M.H., Graubert T.A., et al. A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proc. Natl. Acad. Sci. USA 100 (2003) 14275-14280
30. Lu X., Levine R., Tong W., Wernig G., Pikman Y., Zarnegar S., Gilliland D.G., and Lodish H. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc. Natl. Acad. Sci. USA 102 (2005) 18962-18967
31. Martelli A.M., Nyakern M., Tabellini G., Bortul R., Tazzari P.L., Evangelisti C., and Cocco L. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20 (2006) 911-928
32. Mulloy R., Ferrand A., Kim Y., Sordella R., Bell D.W., Haber D.A., Anderson K.S., and Settleman J. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 67 (2007) 2325-2330
33. Parcells B.W., Ikeda A.K., Simms-Waldrip T., Moore T.B., and Sakamoto K.M. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells 24 (2006) 1174-1184
34. Platanias L.C. Map kinase signaling pathways and hematologic malignancies. Blood 101 (2003) 4667-4679
35. Plaza-Menacho I., Burzynski G.M., de Groot J.W., Eggen B.J., and Hofstra R.M. Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet. 22 (2006) 627-636
36. Reindl C., Bagrintseva K., Vempati S., Schnittger S., Ellwart J.W., Wenig K., Hopfner K.P., Hiddemann W., and Spiekermann K. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood 107 (2006) 3700-3707
37. Rocnik J.L., Okabe R., Yu J.C., Lee B.H., Giese N., Schenkein D.P., and Gilliland D.G. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood 108 (2006) 1339-1345
38. Root D.E., Hacohen N., Hahn W.C., Lander E.S., and Sabatini D.M. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat. Methods 3 (2006) 715-719
39. Rubin A.F., and Green P. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science 317 (2007) 1500
40. Schittenhelm M.M., Yee K.W., Tyner J.W., McGreevey L., Haley A.D., Town A., Griffith D.J., Bainbridge T., Braziel R.M., O'Farrell A.M., et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia 20 (2006) 2008-2014
41. Schnittger S., Kohl T.M., Leopold N., Schoch C., Wichmann H.E., Kern W., Lohse P., Hiddemann W., Haferlach T., and Spiekermann K. D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias. Genes Chromosomes Cancer 45 (2006) 332-337
42. Scholl C., Bansal D., Dohner K., Eiwen K., Huntly B.J., Lee B.H., Rucker F.G., Schlenk R.F., Bullinger L., Dohner H., et al. The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. J. Clin. Invest. 117 (2007) 1037-1048
43. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
44. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007) 561-566
45. Spiekermann K., Dirschinger R.J., Schwab R., Bagrintseva K., Faber F., Buske C., Schnittger S., Kelly L.M., Gilliland D.G., and Hiddemann W. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 101 (2003) 1494-1504
46. Stirewalt D.L., Meshinchi S., Kussick S.J., Sheets K.M., Pogosova-Agadjanyan E., Willman C.L., and Radich J.P. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. Br. J. Haematol. 124 (2004) 481-484
47. Stirewalt D.L., and Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer 3 (2003) 650-665
48. Syampurnawati M., Tatsumi E., Furuta K., and Hayashi Y. Four novel point mutations in exons 12, 13, and 14 of the FLT3 gene. Leuk. Res. 31 (2007) 877
49. The International HapMap Consortium. The International HapMap Project. Nature 426 (2003) 789-796
50. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., Wermke M., Bornhauser M., Ritter M., Neubauer A., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99 (2002) 4326-4335
51. Thomas R.K., Baker A.C., Debiasi R.M., Winckler W., Laframboise T., Lin W.M., Wang M., Feng W., Zander T., Macconnaill L.E., et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39 (2007) 347-351
52. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., and Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
53. Weisberg E., Boulton C., Kelly L.M., Manley P., Fabbro D., Meyer T., Gilliland D.G., and Griffin J.D. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1 (2002) 433-443
54. Whitman S.P., Archer K.J., Feng L., Baldus C., Becknell B., Carlson B.D., Carroll A.J., Mrozek K., Vardiman J.W., George S.L., et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A cancer and leukemia group B study. Cancer Res. 61 (2001) 7233-7239
55. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., Shen D., Boca S.M., Barber T., Ptak J., et al. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007) 1108-1113
56. Yanada M., Matsuo K., Suzuki T., Kiyoi H., and Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: A meta-analysis. Leukemia 19 (2005) 1345-1349